Report: Intel to open worksite clinic for employees
HILLSBORO, Ore. — Intel is helping its employees gain convenient access to health care with the opening this week of an on-site medical center at its Jones Farm Campus in Hillsboro, which will be operated by Walgreens’ Take Care Health Systems, according to local news reports.
Later this year, Intel is looking to open a second worksite medical clinic at is Ronler Acres Campus, according to reports.
The 5,000-sq.-ft. Health for Life Center will give Intel employees access to a full-time physician, nurse practitioners, registered nurses, medical assistants, a physical therapist, phlebotomists and health coaches, according to reports.
Services include urgent care, routine primary care, lab testing, vaccinations, physical therapy, pharmacy services and fitness training. The medical center also will identify chronic health conditions and provide education on how to reduce risk factors, reports stated.
Diabetes Forecast releases 2011 consumer guide
NEW YORK — The magazine of the American Diabetes Association has released its annual consumer guide in its January issue.
Diabetes Forecast highlighted what’s new and on the horizon for the six categories of diabetes-management products, including blood-glucose meters and insulin pens and pumps, as well as diabetes drugs available in the United States, ranked by type and popularity. The guide also spotlighted mobile applications and what devices they can be used for.
The magazine publishes the guide to help diabetics select products that best meet their needs, the American Diabetes Association said.
Click here to read the full guide.
Pfizer inks deal with Santaris
SAN DIEGO — Pfizer will pay Danish biotech company Santaris Pharma $14 million for access to its development platform for RNA-based therapies, Pfizer said Tuesday.
The drug maker said the deal would expand on an existing one between Hoersholm, Denmark-based Santaris and Wyeth, which Pfizer acquired in 2009. Santaris could take in up to $600 million in milestone payments, as well as royalties on products developed under the collaboration.
Santaris’ locked nucleic acid, or LNA, platform is designed for the development of RNA-targeted drugs, which Pfizer said could fight diseases in ways that pharmaceuticals and even biotech drugs, such as monoclonal antibodies, cannot.
“The expansion of our collaboration with Santaris Pharma A/S demonstrates our strategic intention to partner with innovative biopharm/biotech companies to explore novel drug design technologies as a potential source for breakthrough therapeutics,” said Mikael Dolsten, Pfizer president for worldwide research and development.